| 000 | 01717 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516115653.0 | ||
| 264 | 0 | _c20130531 | |
| 008 | 201305s 0 0 eng d | ||
| 022 | _a1873-3492 | ||
| 024 | 7 |
_a10.1016/j.cca.2012.10.028 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMino, Yasuaki | |
| 245 | 0 | 0 |
_aHydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. _h[electronic resource] |
| 260 |
_bClinica chimica acta; international journal of clinical chemistry _cJan 2013 |
||
| 300 |
_a128-32 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntifungal Agents _xblood |
| 650 | 0 | 4 | _aChromatography, Liquid |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGlomerular Filtration Rate |
| 650 | 0 | 4 |
_aHematologic Neoplasms _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunocompromised Host |
| 650 | 0 | 4 |
_aImmunoproliferative Disorders _xblood |
| 650 | 0 | 4 |
_aItraconazole _xanalogs & derivatives |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMycoses _xprevention & control |
| 650 | 0 | 4 |
_aSerum Albumin _xanalysis |
| 650 | 0 | 4 | _aSolutions |
| 650 | 0 | 4 | _aTandem Mass Spectrometry |
| 700 | 1 | _aNaito, Takafumi | |
| 700 | 1 | _aWatanabe, Takayuki | |
| 700 | 1 | _aYamada, Takahiro | |
| 700 | 1 | _aYagi, Tatsuya | |
| 700 | 1 | _aYamada, Hiroshi | |
| 700 | 1 | _aKawakami, Junichi | |
| 773 | 0 |
_tClinica chimica acta; international journal of clinical chemistry _gvol. 415 _gp. 128-32 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.cca.2012.10.028 _zAvailable from publisher's website |
| 999 |
_c22204218 _d22204218 |
||